- Start date
- 07 Dec 2024
- End date
- 07 Dec 2024
- Location
- Room 324
Programme
12:45
Welcome and introduction
Ilaria Colombo, Bellinzona, Switzerland
12:50
Insights from the biology of cancer of the ovaries, fallopian tube and peritoneum: The promise of biomarkers
Kosei Hasegawa, Saitama, Japan
13:02
A clinical case of a patient with platinum-resistant ovarian cancer: Resistance pathways and state-of-the-art treatment options
Asima Mukhopadhyay, Kolkata, India
13:14
The promise of antibody drug conjugates (ADCs) in ovarian cancer: Mechanisms of action and emerging therapeutics
Clare L. Scott, Parkville, VIC, Australia
13:26
A clinical case of a patient on anti-folate receptor ADC: Efficacy and safety data from registrational trials
Ilaria Colombo, Bellinzona, Switzerland
13:38
Q&A, discussion and concluding remarks
Clare L. Scott, Parkville, VIC, Australia
Learning objectives
- To be provided insights on the biological pathways involved in ovarian carcinogenesis, biomarkers and in the mechanisms of primary resistance to platinum-based therapies
- To be informed on the state-of-the-art management of patients with platinum-resistant cancer of the ovaries, fallopian tubes or peritoneum
- To obtain knowledge about novel and emerging treatment options based on antibody drug conjugates (ADCs) for patients with relapsed cancer of the ovaries, fallopian tubes or peritoneum
